Could a vaccine finally stop the 'Snail Fever'?

NCT ID NCT05762393

Completed ⭐️ VACCINE ⭐️ Sponsor: International Vaccine Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new vaccine called SchistoShield® in 120 healthy adults in Burkina Faso and Madagascar. The goal was to see if it is safe and triggers an immune response against schistosomiasis, a parasitic disease spread by snails. Participants received three doses of the vaccine or a placebo, with different strengths being tested.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SchistoShield® vaccine (rSm-p80 antigen with GLA-SE adjuvant)
What this could lead to: If successful, this could lead to the first vaccine to prevent schistosomiasis, a parasitic disease affecting millions.
What could go wrong: This is an early Phase 1b trial focused on safety and immune response, not yet on preventing infection. The vaccine may not provide sufficient protection or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHISTOSOMIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schistosomiasis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHISTOSOMIASIS

Contacts and locations

Locations

Groupe de Recherche Action en Santé (GRAS)

Ouagadougou, Burkina Faso
Madagascar Institute for Vaccine Research (University of Antananarivo)

Antananarivo, Madagascar

More trials for these conditions

Other studies related to the condition(s) this trial covers.